{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:59:17Z","timestamp":1788321557044,"version":"build-2803163510"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03414-6","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T21:00:55Z","timestamp":1775854855000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Recent Advances in Surface-Engineered Polymeric Nanoparticles for Targeted Paclitaxel Delivery in Breast Cancer Therapy"],"prefix":"10.1208","volume":"27","author":[{"given":"Mahak","family":"Fatima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"AlQahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0890-769X","authenticated-orcid":false,"given":"Prashant","family":"Kesharwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"3414_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13058-020-01296-5\/TABLES\/3","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22:1\u201313. https:\/\/doi.org\/10.1186\/S13058-020-01296-5\/TABLES\/3.","journal-title":"Breast Cancer Res"},{"key":"3414_CR2","doi-asserted-by":"publisher","first-page":"101613","DOI":"10.1016\/j.jddst.2020.101613","volume":"56","author":"P Tagde","year":"2020","unstructured":"Tagde P, Kulkarni GT, Mishra DK, Kesharwani P. Recent advances in folic acid engineered nanocarriers for treatment of breast cancer. J Drug Deliv Sci Technol. 2020;56:101613. https:\/\/doi.org\/10.1016\/j.jddst.2020.101613.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3414_CR3","doi-asserted-by":"publisher","unstructured":"Singh S, Numan A, Maddiboyina B, Arora S, Riadi Y, Md S, Alhakamy NA, Kesharwani P. The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer. Drug Discov Today. 2021. https:\/\/doi.org\/10.1016\/j.drudis.2021.03.011.","DOI":"10.1016\/j.drudis.2021.03.011"},{"key":"3414_CR4","doi-asserted-by":"publisher","first-page":"614290","DOI":"10.3389\/fphar.2020.614290","volume":"11","author":"GS Bhagwat","year":"2020","unstructured":"Bhagwat GS, Athawale RB, Gude RP, Md S, Alhakamy NA, Fahmy UA, et al. Formulation and Development of Transferrin Targeted Solid Lipid Nanoparticles for Breast Cancer Therapy. Front Pharmacol. 2020;11:614290. https:\/\/doi.org\/10.3389\/fphar.2020.614290.","journal-title":"Front Pharmacol"},{"key":"3414_CR5","doi-asserted-by":"publisher","unstructured":"Chadar R, Afsana, Kesharwani P. Nanotechnology-based siRNA delivery strategies for treatment of triple negative breast cancer. Int J Pharm. 2021;605. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120835.","DOI":"10.1016\/j.ijpharm.2021.120835"},{"key":"3414_CR6","doi-asserted-by":"publisher","first-page":"087","DOI":"10.1016\/j.biopha.2017.06.087","volume":"93","author":"Z Hussain","year":"2017","unstructured":"Hussain Z, Thu HE, Shuid AN, Kesharwani P, Khan S, Hussain F. Phytotherapeutic potential of natural herbal medicines for the treatment of mild-to-severe atopic dermatitis: A review of human clinical studies. Biomed Pharmacother. 2017;93:087. https:\/\/doi.org\/10.1016\/j.biopha.2017.06.087.","journal-title":"Biomed Pharmacother"},{"key":"3414_CR7","doi-asserted-by":"publisher","first-page":"112044","DOI":"10.1016\/j.colsurfb.2021.112044","volume":"208","author":"R Chadar","year":"2021","unstructured":"Chadar R, Afzal O, Alqahtani SM, Kesharwani P. Carbon nanotubes as an emerging nanocarrier for the delivery of doxorubicin for improved chemotherapy. Colloids Surfaces B Biointerfaces. 2021;208:112044. https:\/\/doi.org\/10.1016\/j.colsurfb.2021.112044.","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"3414_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2024.1405491\/BIBTEX","volume":"14","author":"N Xiong","year":"2024","unstructured":"Xiong N, Wu H, Yu Z. Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies. Front Oncol. 2024;14:1405491. https:\/\/doi.org\/10.3389\/FONC.2024.1405491\/BIBTEX.","journal-title":"Front Oncol"},{"key":"3414_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2021.112530","volume":"146","author":"A Sheikh","year":"2022","unstructured":"Sheikh A, Md S, Kesharwani P. Aptamer grafted nanoparticle as targeted therapeutic tool for the treatment of breast cancer. Biomed Pharmacother. 2022;146:112530. https:\/\/doi.org\/10.1016\/J.BIOPHA.2021.112530.","journal-title":"Biomed Pharmacother"},{"key":"3414_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/J.EURPOLYMJ.2023.111898","volume":"187","author":"TT Dongsar","year":"2023","unstructured":"Dongsar TT, Dongsar TS, Abourehab MAS, Gupta N, Kesharwani P. Emerging application of magnetic nanoparticles for breast cancer therapy. Eur Polym J. 2023;187:111898. https:\/\/doi.org\/10.1016\/J.EURPOLYMJ.2023.111898.","journal-title":"Eur Polym J"},{"key":"3414_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/J.EURPOLYMJ.2021.110746","volume":"159","author":"A Sheikh","year":"2021","unstructured":"Sheikh A, Kesharwani P. An insight into aptamer engineered dendrimer for cancer therapy. Eur Polym J. 2021;159:110746. https:\/\/doi.org\/10.1016\/J.EURPOLYMJ.2021.110746.","journal-title":"Eur Polym J"},{"key":"3414_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.120043","volume":"592","author":"S Paroha","year":"2020","unstructured":"Paroha S, Verma J, Dubey RD, Dewangan RP, Molugulu N, Bapat RA, et al. Recent advances and prospects in gemcitabine drug delivery systems. Int J Pharm. 2020;592:120043. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.120043.","journal-title":"Int J Pharm"},{"key":"3414_CR13","doi-asserted-by":"publisher","first-page":"047","DOI":"10.1016\/j.jcis.2016.07.047","volume":"482","author":"HK Patel","year":"2016","unstructured":"Patel HK, Gajbhiye V, Kesharwani P, Jain NK. Ligand anchored poly(propyleneimine) dendrimers for brain targeting: Comparative in vitro and in vivo assessment. J Colloid Interface Sci. 2016;482:047. https:\/\/doi.org\/10.1016\/j.jcis.2016.07.047.","journal-title":"J Colloid Interface Sci"},{"key":"3414_CR14","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1021\/acs.molpharmaceut.5b00827","volume":"12","author":"MW Amjad","year":"2015","unstructured":"Amjad MW, Amin MCIM, Katas H, Butt AM, Kesharwani P, Iyer AK. In vivo antitumor activity of folate-conjugated cholic acid-polyethylenimine micelles for the codelivery of doxorubicin and siRNA to colorectal adenocarcinomas. Mol Pharm. 2015;12:4247\u201358. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00827.","journal-title":"Mol Pharm"},{"issue":"1","key":"3414_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12943-023-01854-3","volume":"22","author":"N Hasan","year":"2023","unstructured":"Hasan N, Nadaf A, Imran M, Jiba U, Sheikh A, Almalki WH, et al. Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches. Mol Cancer. 2023;22(1):1\u201370. https:\/\/doi.org\/10.1186\/S12943-023-01854-3.","journal-title":"Mol Cancer"},{"key":"3414_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2024.117327","volume":"179","author":"L Gao","year":"2024","unstructured":"Gao L, Meng F, Yang Z, Lafuente-Merchan M, Fern\u00e1ndez LM, Cao Y, et al. Nano-drug delivery system for the treatment of multidrug-resistant breast cancer: current status and future perspectives. Biomed Pharmacother. 2024;179:117327. https:\/\/doi.org\/10.1016\/J.BIOPHA.2024.117327.","journal-title":"Biomed Pharmacother"},{"key":"3414_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/BIOM9120789","volume":"9","author":"TMA Samaan","year":"2019","unstructured":"Samaan TMA, Samec M, Liskova A, Kubatka P, B\u00fcsselberg D. Paclitaxel\u2019s mechanistic and clinical effects on breast cancer. Biomolecules. 2019;9:789. https:\/\/doi.org\/10.3390\/BIOM9120789.","journal-title":"Biomolecules"},{"key":"3414_CR18","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.colsurfb.2016.08.059","volume":"148","author":"M Nag","year":"2016","unstructured":"Nag M, Gajbhiye V, Kesharwani P, Jain NK. Transferrin functionalized chitosan-PEG nanoparticles for targeted delivery of paclitaxel to cancer cells. Colloids Surf B Biointerfaces. 2016;148:363\u201370. https:\/\/doi.org\/10.1016\/j.colsurfb.2016.08.059.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3414_CR19","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.msec.2018.05.054","volume":"91","author":"B Gorain","year":"2018","unstructured":"Gorain B, Choudhury H, Pandey M, Kesharwani P. Paclitaxel loaded vitamin E-TPGS nanoparticles for cancer therapy. Mater Sci Eng C Mater Biol. 2018;91:868\u201380. https:\/\/doi.org\/10.1016\/j.msec.2018.05.054.","journal-title":"Mater Sci Eng C Mater Biol"},{"key":"3414_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.5138\/ijaps.v2i1.289","volume":"2","author":"P Kesarwani","year":"2011","unstructured":"Kesarwani P, Tekade RK, Jain NK. Spectrophotometric estimation of paclitaxel. Int J Adv Pharm Sci. 2011;2:289. https:\/\/doi.org\/10.5138\/ijaps.v2i1.289.","journal-title":"Int J Adv Pharm Sci"},{"key":"3414_CR21","doi-asserted-by":"publisher","unstructured":"Meher JG, Dixit S, Pathan DK, Singh Y, Chandasana H, Pawar VK, Sharma M, Bhatta RS, Konwar R, Kesharwani P, Chourasia MK. Paclitaxel-loaded TPGS enriched self-emulsifying carrier causes apoptosis by modulating survivin expression and inhibits tumour growth in syngeneic mammary tumours. Artif Cells Nanomedicine Biotechnol. 2018;1\u201315. https:\/\/doi.org\/10.1080\/21691401.2018.1492933.","DOI":"10.1080\/21691401.2018.1492933"},{"key":"3414_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/J.PROCBIO.2024.04.007","volume":"142","author":"A Nadaf","year":"2024","unstructured":"Nadaf A, Hasan N, Ahmad S, Gupta A, Jain D, Imtiyaz K, et al. Leucocyte membrane camouflaged poly-lactic-co-glycolic acid (PLGA) nanoparticles containing cannabidiol and paclitaxel against breast cancer therapy. Process Biochem. 2024;142:88\u2013103. https:\/\/doi.org\/10.1016\/J.PROCBIO.2024.04.007.","journal-title":"Process Biochem"},{"key":"3414_CR23","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/J.JPHA.2022.08.002","volume":"12","author":"J Ye","year":"2022","unstructured":"Ye J, Li L, Yin J, Wang H, Li R, Yang Y, et al. Tumor-targeting intravenous lipid emulsion of paclitaxel: characteristics, stability, toxicity, and toxicokinetics. J Pharm Anal. 2022;12:901\u201312. https:\/\/doi.org\/10.1016\/J.JPHA.2022.08.002.","journal-title":"J Pharm Anal"},{"key":"3414_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/FCELL.2021.626910","volume":"9","author":"Y Ma","year":"2021","unstructured":"Ma Y, Yu S, Ni S, Zhang B, Kung ACF, Gao J, et al. Targeting strategies for enhancing paclitaxel specificity in chemotherapy. Front Cell Dev Biol. 2021;9:626910. https:\/\/doi.org\/10.3389\/FCELL.2021.626910.","journal-title":"Front Cell Dev Biol"},{"key":"3414_CR25","doi-asserted-by":"publisher","first-page":"1024143","DOI":"10.3389\/FBIOE.2022.1024143","volume":"10","author":"X Xiao","year":"2022","unstructured":"Xiao X, Teng F, Shi C, Chen J, Wu S, Wang B, et al. Polymeric nanoparticles\u2014Promising carriers for cancer therapy. Front Bioeng Biotechnol. 2022;10:1024143. https:\/\/doi.org\/10.3389\/FBIOE.2022.1024143.","journal-title":"Front Bioeng Biotechnol"},{"key":"3414_CR26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.progpolymsci.2013.07.005","volume":"39","author":"P Kesharwani","year":"2014","unstructured":"Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Prog Polym Sci. 2014;39:268\u2013307. https:\/\/doi.org\/10.1016\/j.progpolymsci.2013.07.005.","journal-title":"Prog Polym Sci"},{"key":"3414_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101565","volume":"56","author":"L Devi","year":"2020","unstructured":"Devi L, Gupta R, Jain SK, Singh S, Kesharwani P. Synthesis, characterization and in vitro assessment of colloidal gold nanoparticles of gemcitabine with natural polysaccharides for treatment of breast cancer. J Drug Deliv Sci Technol. 2020;56:101565. https:\/\/doi.org\/10.1016\/j.jddst.2020.101565.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3414_CR28","doi-asserted-by":"publisher","unstructured":"Meka VS, Sing MKG, Pichika MR, Nali SR, Kolapalli VRM, Kesharwani P. A comprehensive review on polyelectrolyte complexes. Drug Discov Today. 2017.https:\/\/doi.org\/10.1016\/j.drudis.2017.06.008.","DOI":"10.1016\/j.drudis.2017.06.008"},{"key":"3414_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/J.NANO.2010.10.010","volume":"7","author":"P Kesharwani","year":"2011","unstructured":"Kesharwani P, Tekade RK, Gajbhiye V, Jain K, Jain NK. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomedicine. 2011;7:295\u2013304. https:\/\/doi.org\/10.1016\/J.NANO.2010.10.010.","journal-title":"Nanomedicine"},{"key":"3414_CR30","doi-asserted-by":"publisher","unstructured":"Butt AM, Amin MCIM, Katas H, Abdul Murad NA, Jamal R, Kesharwani P. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors. Mol. Pharm. 2016;13.https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b00776.","DOI":"10.1021\/acs.molpharmaceut.6b00776"},{"key":"3414_CR31","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ijpharm.2019.05.042","volume":"565","author":"H Choudhury","year":"2019","unstructured":"Choudhury H, Gorain B, Pandey M, Khurana RK, Kesharwani P. Strategizing biodegradable polymeric nanoparticles to cross the biological barriers for cancer targeting. Int J Pharm. 2019;565:509\u201322. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.05.042.","journal-title":"Int J Pharm"},{"key":"3414_CR32","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.2217\/nnm-2017-0011","volume":"12","author":"A Jain","year":"2017","unstructured":"Jain A, Sharma G, Kushwah V, Garg NK, Kesharwani P, Ghoshal G, et al. Methotrexate and beta-carotene loaded-lipid polymer hybrid nanoparticles: a preclinical study for breast cancer. Nanomedicine. 2017;12:1851\u201372. https:\/\/doi.org\/10.2217\/nnm-2017-0011.","journal-title":"Nanomedicine"},{"key":"3414_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2024.117372","volume":"179","author":"SS Naser","year":"2024","unstructured":"Naser SS, Gupta A, Choudhury A, Yadav A, Sinha A, Kirti A, et al. Biophysical translational paradigm of polymeric nanoparticle: embarked advancement to brain tumor therapy. Biomed Pharmacother. 2024;179:117372. https:\/\/doi.org\/10.1016\/J.BIOPHA.2024.117372.","journal-title":"Biomed Pharmacother"},{"key":"3414_CR34","doi-asserted-by":"publisher","first-page":"9118","DOI":"10.3390\/IJMS22179118","volume":"22","author":"W Xia","year":"2021","unstructured":"Xia W, Tao Z, Zhu B, Zhang W, Liu C, Chen S, et al. Targeted delivery of drugs and genes using polymer nanocarriers for cancer therapy. Int J Mol Sci. 2021;22:9118. https:\/\/doi.org\/10.3390\/IJMS22179118.","journal-title":"Int J Mol Sci"},{"key":"3414_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s11051-013-1625-2","volume":"15","author":"S Thakur","year":"2013","unstructured":"Thakur S, Tekade RK, Kesharwani P, Jain NK. The effect of polyethylene glycol spacer chain length on the tumor-targeting potential of folate-modified PPI dendrimers. J Nanoparticle Res. 2013;15:1625. https:\/\/doi.org\/10.1007\/s11051-013-1625-2.","journal-title":"J Nanoparticle Res"},{"key":"3414_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/J.EURPOLYMJ.2022.111471","volume":"177","author":"S Mukherjee","year":"2022","unstructured":"Mukherjee S, Mukherjee S, Abourehab MAS, Sahebkar A, Kesharwani P. Exploring dendrimer-based drug delivery systems and their potential applications in cancer immunotherapy. Eur Polym J. 2022;177:111471. https:\/\/doi.org\/10.1016\/J.EURPOLYMJ.2022.111471.","journal-title":"Eur Polym J"},{"key":"3414_CR37","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/J.JCONREL.2021.08.003","volume":"337","author":"H Kaur","year":"2021","unstructured":"Kaur H, Kesharwani P. Advanced nanomedicine approaches applied for treatment of skin carcinoma. J Control Release. 2021;337:589\u2013611. https:\/\/doi.org\/10.1016\/J.JCONREL.2021.08.003.","journal-title":"J Control Release"},{"key":"3414_CR38","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.drudis.2015.05.004","volume":"20","author":"P Kesharwani","year":"2015","unstructured":"Kesharwani P, Mishra V, Jain NK. Validating the anticancer potential of carbon nanotube-based therapeutics through cell line testing. Drug Discov Today. 2015;20:1049\u201360. https:\/\/doi.org\/10.1016\/j.drudis.2015.05.004.","journal-title":"Drug Discov Today"},{"issue":"1","key":"3414_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12943-023-01849-0","volume":"22","author":"KR Gajbhiye","year":"2023","unstructured":"Gajbhiye KR, Salve R, Narwade M, Sheikh A, Kesharwani P, Gajbhiye V. Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics. Mol Cancer. 2023;22(1):1\u201344. https:\/\/doi.org\/10.1186\/S12943-023-01849-0.","journal-title":"Mol Cancer"},{"key":"3414_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/BIOMEDICINES9020114","volume":"9","author":"S Jahan","year":"2021","unstructured":"Jahan S, Karim ME, Chowdhury EH. Nanoparticles targeting receptors on breast cancer for efficient delivery of chemotherapeutics. Biomedicines. 2021;9:114. https:\/\/doi.org\/10.3390\/BIOMEDICINES9020114.","journal-title":"Biomedicines"},{"key":"3414_CR41","doi-asserted-by":"publisher","unstructured":"Kenguva G, Rout SR, Fatima M, Dubey SK, Alexander A, Abourehab MAS, Kesharwani P, Dandela R. Solubility enhancement and drug release mechanism of polymeric micelles. Polym Micelles Drug Deliv. 2022;41\u201364. https:\/\/doi.org\/10.1016\/B978-0-323-89868-3.00006-9.","DOI":"10.1016\/B978-0-323-89868-3.00006-9"},{"key":"3414_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJPHARM.2023.123270","volume":"643","author":"L Siddiqui","year":"2023","unstructured":"Siddiqui L, Hasan N, Mishra PK, Gupta N, Singh AT, Madaan A, et al. CD44 mediated colon cancer targeting mutlifaceted lignin nanoparticles: synthesis, in vitro characterization and in vivo efficacy studies. Int J Pharm. 2023;643:123270. https:\/\/doi.org\/10.1016\/J.IJPHARM.2023.123270.","journal-title":"Int J Pharm"},{"key":"3414_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/J.JDDST.2023.104943","volume":"88","author":"HS Sardou","year":"2023","unstructured":"Sardou HS, Nazari SE, Abbaspour M, Akhgari A, Sheikh A, Kesharwani P, et al. Nano-curcumin formulations for targeted therapy of colorectal cancer. J Drug Deliv Sci Technol. 2023;88:104943. https:\/\/doi.org\/10.1016\/J.JDDST.2023.104943.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3414_CR44","doi-asserted-by":"publisher","unstructured":"Kar A, Rout SR, Singh V, Greish K, Sahebkar A, Abourehab MAS, Kesharwani P, Dandela R. Triblock polymeric micelles as an emerging nanocarrier for drug delivery. Polym Micelles Drug Deliv. 2022;561\u2013590. https:\/\/doi.org\/10.1016\/B978-0-323-89868-3.00022-7.","DOI":"10.1016\/B978-0-323-89868-3.00022-7"},{"key":"3414_CR45","doi-asserted-by":"publisher","unstructured":"Gorain B, Choudhury H, Pandey M, Kokare C, Khurana RK, Sehdev A. Polyester, Polyhydroxyalkanoate Nanoparticles as a Promising Tool for Anticancer Therapeutics, Polym. Nanoparticles as a Promis. Tool Anti-Cancer Ther. 2019;101\u2013121. https:\/\/doi.org\/10.1016\/B978-0-12-816963-6.00006-6.","DOI":"10.1016\/B978-0-12-816963-6.00006-6"},{"key":"3414_CR46","doi-asserted-by":"publisher","first-page":"101400","DOI":"10.1016\/J.MTCHEM.2023.101400","volume":"29","author":"SM Hosseini","year":"2023","unstructured":"Hosseini SM, Mohammadnejad J, Salamat S, Beiram Zadeh Z, Tanhaei M, Ramakrishna S. Theranostic polymeric nanoparticles as a new approach in cancer therapy and diagnosis: a review. Mater Today Chem. 2023;29:101400. https:\/\/doi.org\/10.1016\/J.MTCHEM.2023.101400.","journal-title":"Mater Today Chem"},{"key":"3414_CR47","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/J.ADDR.2015.09.012","volume":"99","author":"JS Suk","year":"2015","unstructured":"Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2015;99:28. https:\/\/doi.org\/10.1016\/J.ADDR.2015.09.012.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"3414_CR48","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/CELLS14020061","volume":"14","author":"E Pashkina","year":"2025","unstructured":"Pashkina E, Bykova M, Berishvili M, Lazarev Y, Kozlov V. Hyaluronic Acid-Based Drug Delivery Systems for Cancer Therapy. Cells. 2025;14(2):61. https:\/\/doi.org\/10.3390\/CELLS14020061.","journal-title":"Cells"},{"key":"3414_CR49","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1080\/10717544.2022.2089296","volume":"29","author":"R Bajracharya","year":"2022","unstructured":"Bajracharya R, Song JG, Patil BR, Lee SH, Noh HM, Kim DH, et al. Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems. Drug Deliv. 2022;29:1959. https:\/\/doi.org\/10.1080\/10717544.2022.2089296.","journal-title":"Drug Deliv"},{"issue":"3","key":"3414_CR50","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/RECEPTORS3030016","volume":"3","author":"A Prajapati","year":"2024","unstructured":"Prajapati A, Rangra S, Patil R, Desai N, Jyothi VGSS, Salave S, et al. Receptor-Targeted Nanomedicine for Cancer Therapy. Receptors. 2024;3(3):323\u201361. https:\/\/doi.org\/10.3390\/RECEPTORS3030016.","journal-title":"Receptors"},{"key":"3414_CR51","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.3389\/FPHAR.2019.01628","volume":"10","author":"P Chaubey","year":"2020","unstructured":"Chaubey P, Momin M, Sawarkar S. Significance of ligand-anchored polymers for drug targeting in the treatment of colonic disorders. Front Pharmacol. 2020;10:1628. https:\/\/doi.org\/10.3389\/FPHAR.2019.01628.","journal-title":"Front Pharmacol"},{"key":"3414_CR52","doi-asserted-by":"publisher","unstructured":"Madej M, Kurowska N, Strzalka-Mrozik B. Polymeric Nanoparticles\u2014Tools in a Drug Delivery System in Selected Cancer Therapies. Appl Sci. 2022;12.https:\/\/doi.org\/10.3390\/app12199479.","DOI":"10.3390\/app12199479"},{"key":"3414_CR53","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4274\/TJPS.GALENOS.2021.26529","volume":"20","author":"AK Bawankule","year":"2023","unstructured":"Bawankule AK, Tatode AA, Patil PS, Umekar MJ. Folate-mediated paclitaxel nanodelivery systems: a comprehensive review. Turk J Pharm Sci. 2023;20:58. https:\/\/doi.org\/10.4274\/TJPS.GALENOS.2021.26529.","journal-title":"Turk J Pharm Sci"},{"key":"3414_CR54","doi-asserted-by":"publisher","first-page":"057","DOI":"10.7324\/JAPS.2024.172227","volume":"14","author":"F Al-Sahlawi","year":"2024","unstructured":"Al-Sahlawi F, Alabdali AYM, Chinnappan S, Al-Samydai A, Maki MAA. Polymer-based nanoparticles in targeted cancer therapy: a review. J Appl Pharm Sci. 2024;14:057\u201368. https:\/\/doi.org\/10.7324\/JAPS.2024.172227.","journal-title":"J Appl Pharm Sci"},{"key":"3414_CR55","doi-asserted-by":"publisher","first-page":"28670","DOI":"10.1021\/acsomega.5c02916","volume":"10","author":"A Muley","year":"2025","unstructured":"Muley A, Navale A, Gupta R, Tekade RK. \u201cNano-paclitaxel\u201d unlocking potential and redefining cancer chemotherapy. ACS Omega. 2025;10:28670\u201390. https:\/\/doi.org\/10.1021\/acsomega.5c02916.","journal-title":"ACS Omega"},{"key":"3414_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2022.855294","volume":"13","author":"M Sakhi","year":"2022","unstructured":"Sakhi M, Khan A, Iqbal Z, Khan I, Raza A, Ullah A, et al. Design and characterization of Paclitaxel-loaded polymeric nanoparticles decorated with Trastuzumab for the effective treatment of breast cancer. Front Pharmacol. 2022;13:1\u201315. https:\/\/doi.org\/10.3389\/fphar.2022.855294.","journal-title":"Front Pharmacol"},{"key":"3414_CR57","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ijpharm.2015.11.033","volume":"497","author":"K Yu","year":"2016","unstructured":"Yu K, Zhao J, Zhang Z, Gao Y, Zhou Y, Teng L, et al. Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI\/PLGA nanoparticles against HER-positive breast cancer cells. Int J Pharm. 2016;497:78\u201387. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.11.033.","journal-title":"Int J Pharm"},{"key":"3414_CR58","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1039\/d1bm00370d","volume":"9","author":"KR Kim","year":"2021","unstructured":"Kim KR, You SJ, Kim HJ, Yang DH, Chun HJ, Lee D, et al. Theranostic potential of biodegradable polymeric nanoparticles with paclitaxel and curcumin against breast carcinoma. Biomater Sci. 2021;9:3750\u201361. https:\/\/doi.org\/10.1039\/d1bm00370d.","journal-title":"Biomater Sci"},{"key":"3414_CR59","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1364\/boe.419252","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Pasternak M, Sathiyamoorthy K, Kolios MC. Anti-HER2 PLGA-PEG polymer nanoparticle containing gold nanorods and paclitaxel for laser-activated breast cancer detection and therapy. Biomed Opt Express. 2021;12:2171. https:\/\/doi.org\/10.1364\/boe.419252.","journal-title":"Biomed Opt Express"},{"key":"3414_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109121","volume":"117","author":"T Duan","year":"2019","unstructured":"Duan T, Xu Z, Sun F, Wang Y, Zhang J, Luo C, et al. HPA aptamer functionalized paclitaxel-loaded PLGA nanoparticles for enhanced anticancer therapy through targeted effects and microenvironment modulation. Biomed Pharmacother. 2019;117:109121. https:\/\/doi.org\/10.1016\/j.biopha.2019.109121.","journal-title":"Biomed Pharmacother"},{"key":"3414_CR61","doi-asserted-by":"publisher","unstructured":"Nguyen KT, Vinh Le D, Ho Do D, Huan Le Q. Development of chitosan graft pluronic\u00aeF127 copolymer nanoparticles containing DNA aptamer for paclitaxel delivery to treat breast cancer cells. Adv Nat Sci Nanosci Nanotechnol. 2016;7. https:\/\/doi.org\/10.1088\/2043-6262\/7\/2\/025018.","DOI":"10.1088\/2043-6262\/7\/2\/025018"},{"key":"3414_CR62","doi-asserted-by":"publisher","unstructured":"Dursun A. Enhancement of Paclitaxel Therapeutic Effect by Aptamer Targeted Delivery in PLGA Nanoparticles. Eurasian J Med Investig. 2022;5:422\u2013426. https:\/\/doi.org\/10.14744\/ejmi.2021.12120.","DOI":"10.14744\/ejmi.2021.12120"},{"key":"3414_CR63","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jmmm.2013.05.036","volume":"344","author":"A Aravind","year":"2013","unstructured":"Aravind A, Nair R, Raveendran S, Veeranarayanan S, Nagaoka Y, Fukuda T, et al. Aptamer conjugated paclitaxel and magnetic fluid loaded fluorescently tagged PLGA nanoparticles for targeted cancer therapy. J Magn Magn Mater. 2013;344:116\u201323. https:\/\/doi.org\/10.1016\/j.jmmm.2013.05.036.","journal-title":"J Magn Magn Mater"},{"key":"3414_CR64","doi-asserted-by":"publisher","first-page":"6762","DOI":"10.1039\/c7tb01510k","volume":"5","author":"Z Yang","year":"2017","unstructured":"Yang Z, Sun N, Cheng R, Zhao C, Liu J, Tian Z. Hybrid nanoparticles coated with hyaluronic acid lipoid for targeted co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells. J Mater Chem B. 2017;5:6762\u201375. https:\/\/doi.org\/10.1039\/c7tb01510k.","journal-title":"J Mater Chem B"},{"key":"3414_CR65","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.colsurfb.2016.03.075","volume":"143","author":"E Muntimadugu","year":"2016","unstructured":"Muntimadugu E, Kumar R, Saladi S, Rafeeqi TA, Khan W. Cd44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel. Colloids Surf B Biointerfaces. 2016;143:532\u201346. https:\/\/doi.org\/10.1016\/j.colsurfb.2016.03.075.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3414_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22031257","volume":"22","author":"V Gote","year":"2021","unstructured":"Gote V, Sharma AD, Pal D. Hyaluronic acid-targeted stimuli-sensitive nanomicelles co-encapsulating paclitaxel and ritonavir to overcome multi-drug resistance in metastatic breast cancer and triple-negative breast cancer cells. Int J Mol Sci. 2021;22:1\u201335. https:\/\/doi.org\/10.3390\/ijms22031257.","journal-title":"Int J Mol Sci"},{"key":"3414_CR67","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.actbio.2015.08.029","volume":"26","author":"S Yin","year":"2015","unstructured":"Yin S, Huai J, Chen X, Yang Y, Zhang X, Gan Y, et al. Intracellular delivery and antitumor effects of a redox-responsive polymeric paclitaxel conjugate based on hyaluronic acid. Acta Biomater. 2015;26:274\u201385. https:\/\/doi.org\/10.1016\/j.actbio.2015.08.029.","journal-title":"Acta Biomater"},{"key":"3414_CR68","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1021\/acs.molpharmaceut.9b01148","volume":"17","author":"P Zhong","year":"2020","unstructured":"Zhong P, Chen X, Guo R, Chen X, Chen Z, Wei C, et al. Folic acid-modified nanoerythrocyte for codelivery of paclitaxel and tariquidar to overcome breast cancer multidrug resistance. Mol Pharm. 2020;17:1114\u201326. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b01148.","journal-title":"Mol Pharm"},{"key":"3414_CR69","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.msec.2016.01.059","volume":"62","author":"M Esfandyari-Manesh","year":"2016","unstructured":"Esfandyari-Manesh M, Darvishi B, Ishkuh FA, Shahmoradi E, Mohammadi A, Javanbakht M, et al. Paclitaxel molecularly imprinted polymer-PEG-folate nanoparticles for targeting anticancer delivery: characterization and cellular cytotoxicity. Mater Sci Eng C Mater Biol. 2016;62:626\u201333. https:\/\/doi.org\/10.1016\/j.msec.2016.01.059.","journal-title":"Mater Sci Eng C Mater Biol"},{"key":"3414_CR70","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.2147\/IJN.S77667","volume":"10","author":"L Zhang","year":"2015","unstructured":"Zhang L, Zhu D, Dong X, Sun H, Song C, Wang C, et al. Folate-modified lipid\u2013polymer hybrid nanoparticles for targeted paclitaxel delivery. Int J Nanomedicine. 2015;10:2101\u201314. https:\/\/doi.org\/10.2147\/IJN.S77667.","journal-title":"Int J Nanomedicine"},{"key":"3414_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jrras.2024.101086","volume":"17","author":"NI Hassan","year":"2024","unstructured":"Hassan NI, Mustafa TA, Hassan YM. CO-delivery of paclitaxel and indocyanine green with Koliphore-elp35\/folic acid nanoparticles for NIR-triggered chemo\/photodynamic therapy in MCF-7 and MCF-10 cells. J Radiat Res Appl Sci. 2024;17:101086. https:\/\/doi.org\/10.1016\/j.jrras.2024.101086.","journal-title":"J Radiat Res Appl Sci"},{"key":"3414_CR72","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1080\/10717544.2018.1477863","volume":"25","author":"S Niu","year":"2018","unstructured":"Niu S, Bremner DH, Wu J, Wu J, Wang H, Li H, et al. L-peptide functionalized dual-responsive nanoparticles for controlled paclitaxel release and enhanced apoptosis in breast cancer cells. Drug Deliv. 2018;25:1275\u201388. https:\/\/doi.org\/10.1080\/10717544.2018.1477863.","journal-title":"Drug Deliv"},{"key":"3414_CR73","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1016\/j.biomaterials.2009.11.047","volume":"31","author":"DH Yu","year":"2010","unstructured":"Yu DH, Lu Q, Xie J, Fang C, Chen HZ. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials. 2010;31:2278\u201392. https:\/\/doi.org\/10.1016\/j.biomaterials.2009.11.047.","journal-title":"Biomaterials"},{"key":"3414_CR74","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1016\/j.biomaterials.2011.03.061","volume":"32","author":"M Shahin","year":"2011","unstructured":"Shahin M, Ahmed S, Kaur K, Lavasanifar A. Decoration of polymeric micelles with cancer-specific peptide ligands for active targeting of paclitaxel. Biomaterials. 2011;32:5123\u201333. https:\/\/doi.org\/10.1016\/j.biomaterials.2011.03.061.","journal-title":"Biomaterials"},{"key":"3414_CR75","doi-asserted-by":"publisher","first-page":"110043","DOI":"10.1016\/j.msec.2019.110043","volume":"105","author":"B Gibbens-Bandala","year":"2019","unstructured":"Gibbens-Bandala B, Morales-Avila E, Ferro-Flores G, Santos-Cuevas C, Mel\u00e9ndez-Alafort L, Trujillo-Nolasco M, et al. 177Lu-bombesin-PLGA (paclitaxel): a targeted controlled-release nanomedicine for bimodal therapy of breast cancer. Mater Sci Eng C. 2019;105:110043. https:\/\/doi.org\/10.1016\/j.msec.2019.110043.","journal-title":"Mater Sci Eng C"},{"key":"3414_CR76","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/J.TIPS.2024.10.005","volume":"45","author":"V Blay","year":"2024","unstructured":"Blay V, Pandiella A. Strategies to boost antibody selectivity in oncology. Trends Pharmacol Sci. 2024;45:1135\u201349. https:\/\/doi.org\/10.1016\/J.TIPS.2024.10.005.","journal-title":"Trends Pharmacol Sci"},{"key":"3414_CR77","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3762\/BJNANO.14.75","volume":"14","author":"M Kumari","year":"2023","unstructured":"Kumari M, Acharya A, Krishnamurthy PT. Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics. Beilstein J Nanotechnol. 2023;14:912. https:\/\/doi.org\/10.3762\/BJNANO.14.75.","journal-title":"Beilstein J Nanotechnol"},{"issue":"2","key":"3414_CR78","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2022","unstructured":"Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2022;22(2):101\u201326. https:\/\/doi.org\/10.1038\/s41573-022-00579-0.","journal-title":"Nat Rev Drug Discov"},{"key":"3414_CR79","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/J.CLBC.2018.01.006","volume":"18","author":"K Blackwell","year":"2018","unstructured":"Blackwell K, Gligorov J, Jacobs I, Twelves C. The global need for a Trastuzumab biosimilar for patients with HER2-positive breast cancer. Clin Breast Cancer. 2018;18:95\u2013113. https:\/\/doi.org\/10.1016\/J.CLBC.2018.01.006.","journal-title":"Clin Breast Cancer"},{"key":"3414_CR80","doi-asserted-by":"publisher","unstructured":"Abedin MR, Powers K, Aiardo R, Barua D, Barua S. Antibody\u2013drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells. Sci Rep. 2021; 111 11 1\u201317. https:\/\/doi.org\/10.1038\/s41598-021-86762-6.","DOI":"10.1038\/s41598-021-86762-6"},{"key":"3414_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/J.ADDR.2023.114857","volume":"198","author":"B Wan","year":"2023","unstructured":"Wan B, Bao Q, Burgess D. Long-acting PLGA microspheres: advances in excipient and product analysis toward improved product understanding. Adv Drug Deliv Rev. 2023;198:114857. https:\/\/doi.org\/10.1016\/J.ADDR.2023.114857.","journal-title":"Adv Drug Deliv Rev"},{"key":"3414_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/S12865-021-00405-Z","volume":"22","author":"LAA Kilany","year":"2021","unstructured":"Kilany LAA, Gaber AAS, Aboulwafa MM, Zedan HH. Trastuzumab immunogenicity development in patients\u2019 sera and in laboratory animals. BMC Immunol. 2021;22:15. https:\/\/doi.org\/10.1186\/S12865-021-00405-Z.","journal-title":"BMC Immunol"},{"issue":"20","key":"3414_CR83","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/S11671-025-04303-W","volume":"201","author":"T Dixit","year":"2025","unstructured":"Dixit T, Aswini A, Nikam H, Vaidya A, Ravindran S. Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates. Discov Nano. 2025;201(20):139. https:\/\/doi.org\/10.1186\/S11671-025-04303-W.","journal-title":"Discov Nano"},{"key":"3414_CR84","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/J.JCONREL.2023.09.001","volume":"362","author":"J Casper","year":"2023","unstructured":"Casper J, Schenk SH, Parhizkar E, Detampel P, Dehshahri A, Huwyler J. Polyethylenimine (PEI) in gene therapy: current status and clinical applications. J Control Release. 2023;362:667\u201391. https:\/\/doi.org\/10.1016\/J.JCONREL.2023.09.001.","journal-title":"J Control Release"},{"key":"3414_CR85","doi-asserted-by":"publisher","unstructured":"Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;81(8):1\u201339. https:\/\/doi.org\/10.1038\/s41392-023-01460-1.","DOI":"10.1038\/s41392-023-01460-1"},{"key":"3414_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2022.837952\/FULL","volume":"12","author":"L Li","year":"2022","unstructured":"Li L, Chen X, Yu J, Yuan S. Preliminary clinical application of RGD-containing peptides as PET radiotracers for imaging tumors. Front Oncol. 2022;12:837952. https:\/\/doi.org\/10.3389\/FONC.2022.837952\/FULL.","journal-title":"Front Oncol"},{"key":"3414_CR87","doi-asserted-by":"publisher","unstructured":"Mohan CD, Hari S, Preetham HD, Rangappa S, Barash U, Ilan N, Nayak SC, Gupta VK, Vlodavsky I, Rangappa KS. Targeting Heparanase in Cancer: Inhibition by Synthetic, Chemically Modified, and Natural Compounds. IScience. 2019;15:360\u2013390. https:\/\/doi.org\/10.1016\/J.ISCI.2019.04.034.","DOI":"10.1016\/J.ISCI.2019.04.034"},{"key":"3414_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2021.112232","volume":"143","author":"X Xiao","year":"2021","unstructured":"Xiao X, Li H, Zhao L, Zhang Y, Liu Z. Oligonucleotide aptamers: recent advances in their screening, molecular conformation and therapeutic applications. Biomed Pharmacother. 2021;143:112232. https:\/\/doi.org\/10.1016\/J.BIOPHA.2021.112232.","journal-title":"Biomed Pharmacother"},{"key":"3414_CR89","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/J.DRUP.2016.10.001","volume":"29","author":"I Vlodavsky","year":"2016","unstructured":"Vlodavsky I, Singh P, Boyango I, Gutter-Kapon L, Elkin M, Sanderson RD, et al. Heparanase: from basic research to therapeutic applications in cancer and inflammation. Drug Resist Updat. 2016;29:54. https:\/\/doi.org\/10.1016\/J.DRUP.2016.10.001.","journal-title":"Drug Resist Updat"},{"key":"3414_CR90","doi-asserted-by":"publisher","unstructured":"Jayatilleke KM, Hulett MD. Heparanase and the hallmarks of cancer. J Transl Med. 2020;181(18):1\u201325. https:\/\/doi.org\/10.1186\/S12967-020-02624-1.","DOI":"10.1186\/S12967-020-02624-1"},{"key":"3414_CR91","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3390\/IJMS25021064","volume":"25","author":"E Rubin","year":"2024","unstructured":"Rubin E, Shan KS, Dalal S, Vu DUD, Milillo-Naraine AM, Guaqueta D, et al. Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers. Int J Mol Sci. 2024;25:1064. https:\/\/doi.org\/10.3390\/IJMS25021064.","journal-title":"Int J Mol Sci"},{"key":"3414_CR92","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/J.AJPS.2020.03.003","volume":"16","author":"PI Siafaka","year":"2021","unstructured":"Siafaka PI, Okur N\u00dc, Karantas ID, Okur ME, G\u00fcndo\u011fdu EA. Current update on nanoplatforms as therapeutic and diagnostic tools: a review for the materials used as nanotheranostics and imaging modalities. Asian J Pharm Sci. 2021;16:24\u201346. https:\/\/doi.org\/10.1016\/J.AJPS.2020.03.003.","journal-title":"Asian J Pharm Sci"},{"key":"3414_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/FCHEM.2020.00561","volume":"8","author":"AJ Gauger","year":"2020","unstructured":"Gauger AJ, Hershberger KK, Bronstein LM. Theranostics based on magnetic nanoparticles and polymers: intelligent design for efficient diagnostics and therapy. Front Chem. 2020;8:561. https:\/\/doi.org\/10.3389\/FCHEM.2020.00561.","journal-title":"Front Chem"},{"key":"3414_CR94","doi-asserted-by":"publisher","first-page":"21859","DOI":"10.1021\/AM5036225\/ASSET\/IMAGES\/LARGE\/AM-2014-036225_0010.JPEG","volume":"6","author":"BT Luk","year":"2014","unstructured":"Luk BT, Zhang L. Current advances in polymer-based nanotheranostics for cancer treatment and diagnosis. ACS Appl Mater Interfaces. 2014;6:21859\u201373. https:\/\/doi.org\/10.1021\/AM5036225\/ASSET\/IMAGES\/LARGE\/AM-2014-036225_0010.JPEG.","journal-title":"ACS Appl Mater Interfaces"},{"key":"3414_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/J.LFS.2024.122899","volume":"352","author":"AN Al-Thani","year":"2024","unstructured":"Al-Thani AN, Jan AG, Abbas M, Geetha M, Sadasivuni KK. Nanoparticles in cancer theragnostic and drug delivery: a comprehensive review. Life Sci. 2024;352:122899. https:\/\/doi.org\/10.1016\/J.LFS.2024.122899.","journal-title":"Life Sci"},{"key":"3414_CR96","doi-asserted-by":"publisher","first-page":"101852","DOI":"10.1016\/J.BBREP.2024.101852","volume":"40","author":"A Fallah","year":"2024","unstructured":"Fallah A, Imani Fooladi AA, Havaei SA, Mahboobi M, Sedighian H. Recent advances in aptamer discovery, modification and improving performance. Biochem Biophys Rep. 2024;40:101852. https:\/\/doi.org\/10.1016\/J.BBREP.2024.101852.","journal-title":"Biochem Biophys Rep"},{"key":"3414_CR97","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/NRD.2016.199","volume":"16","author":"J Zhou","year":"2016","unstructured":"Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov. 2016;16:181. https:\/\/doi.org\/10.1038\/NRD.2016.199.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"3414_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13045-018-0605-5","volume":"111","author":"C Chen","year":"2018","unstructured":"Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018;111(11):1\u201323. https:\/\/doi.org\/10.1186\/S13045-018-0605-5.","journal-title":"J Hematol Oncol"},{"key":"3414_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2021.800481","volume":"12","author":"P Kesharwani","year":"2022","unstructured":"Kesharwani P, Chadar R, Sheikh A, Rizg WY, Safhi AY. Cd44-targeted nanocarrier for cancer therapy. Front Pharmacol. 2022;12:800481. https:\/\/doi.org\/10.3389\/FPHAR.2021.800481.","journal-title":"Front Pharmacol"},{"key":"3414_CR100","doi-asserted-by":"publisher","first-page":"13928","DOI":"10.1039\/D1RA01574E","volume":"11","author":"AK Jangid","year":"2021","unstructured":"Jangid AK, Pooja D, Jain P, Gupta N, Ramesan S, Kulhari H. Self-assembled and ph-responsive polymeric nanomicelles impart effective delivery of paclitaxel to cancer cells. RSC Adv. 2021;11:13928\u201339. https:\/\/doi.org\/10.1039\/D1RA01574E.","journal-title":"RSC Adv"},{"key":"3414_CR101","doi-asserted-by":"publisher","DOI":"10.1002\/ADMA.202312939","volume":"36","author":"M Fatima","year":"2024","unstructured":"Fatima M, Almalki WH, Khan T, Sahebkar A, Kesharwani P. Harnessing the power of stimuli-responsive nanoparticles as an effective therapeutic drug delivery system. Adv Mater. 2024;36:2312939. https:\/\/doi.org\/10.1002\/ADMA.202312939.","journal-title":"Adv Mater"},{"key":"3414_CR102","doi-asserted-by":"publisher","first-page":"8047","DOI":"10.1039\/C5PY01355K","volume":"6","author":"T Yin","year":"2015","unstructured":"Yin T, Wang J, Yin L, Shen L, Zhou J, Huo M. Redox-sensitive hyaluronic acid\u2013paclitaxel conjugate micelles with high physical drug loading for efficient tumor therapy. Polym Chem. 2015;6:8047\u201359. https:\/\/doi.org\/10.1039\/C5PY01355K.","journal-title":"Polym Chem"},{"key":"3414_CR103","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/J.APSB.2019.06.004","volume":"9","author":"Z Luo","year":"2019","unstructured":"Luo Z, Dai Y, Gao H. Development and application of hyaluronic acid in tumor targeting drug delivery. Acta Pharm Sin B. 2019;9:1099. https:\/\/doi.org\/10.1016\/J.APSB.2019.06.004.","journal-title":"Acta Pharm Sin B"},{"key":"3414_CR104","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/IJMS242115812","volume":"24","author":"N Cirillo","year":"2023","unstructured":"Cirillo N. The Hyaluronan\/CD44 Axis: A Double-Edged Sword in Cancer. Int J Mol Sci. 2023;24:24. https:\/\/doi.org\/10.3390\/IJMS242115812.","journal-title":"Int J Mol Sci"},{"key":"3414_CR105","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1021\/ACS.MOLPHARMACEUT.9B00083","volume":"16","author":"A Spadea","year":"2019","unstructured":"Spadea A, Rios De La Rosa JM, Tirella A, Ashford MB, Williams KJ, Stratford IJ, et al. Evaluating the efficiency of hyaluronic acid for tumor targeting via CD44. Mol Pharm. 2019;16:2481\u201393. https:\/\/doi.org\/10.1021\/ACS.MOLPHARMACEUT.9B00083.","journal-title":"Mol Pharm"},{"key":"3414_CR106","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1039\/D3SC05539F","volume":"15","author":"M Ahmadi","year":"2024","unstructured":"Ahmadi M, Ritter CA, von Woedtke T, Bekeschus S, Wende K. Package delivered: folate receptor-mediated transporters in cancer therapy and diagnosis. Chem Sci. 2024;15:1966\u20132006. https:\/\/doi.org\/10.1039\/D3SC05539F.","journal-title":"Chem Sci"},{"key":"3414_CR107","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1021\/ACSMEDCHEMLETT.0C00031\/SUPPL_FILE\/ML0C00031_SI_001.PDF","volume":"11","author":"X Jin","year":"2020","unstructured":"Jin X, Zhang J, Jin X, Liu L, Tian X. Folate receptor targeting and cathepsin B-sensitive drug delivery system for selective cancer cell death and imaging. ACS Med Chem Lett. 2020;11:1514\u201320. https:\/\/doi.org\/10.1021\/ACSMEDCHEMLETT.0C00031\/SUPPL_FILE\/ML0C00031_SI_001.PDF.","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"3414_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12951-022-01748-4","volume":"20","author":"E Soprano","year":"2022","unstructured":"Soprano E, Polo E, Pelaz B, del Pino P. Biomimetic cell-derived nanocarriers in cancer research. J Nanobiotechnol. 2022;20(1):1\u201316. https:\/\/doi.org\/10.1186\/S12951-022-01748-4.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"3414_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12951-022-01251-W","volume":"20","author":"W Lei","year":"2022","unstructured":"Lei W, Yang C, Wu Y, Ru G, He X, Tong X, et al. Nanocarriers surface engineered with cell membranes for cancer targeted chemotherapy. J Nanobiotechnol. 2022;20(1):1\u201321. https:\/\/doi.org\/10.1186\/S12951-022-01251-W.","journal-title":"J Nanobiotechnol"},{"key":"3414_CR110","doi-asserted-by":"publisher","DOI":"10.1002\/ADVS.202206150","volume":"10","author":"Z Luo","year":"2022","unstructured":"Luo Z, Sun L, Bian F, Wang Y, Yu Y, Gu Z, et al. Erythrocyte\u2010inspired functional materials for biomedical applications. Adv Sci. 2022;10:2206150. https:\/\/doi.org\/10.1002\/ADVS.202206150.","journal-title":"Adv Sci"},{"key":"3414_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/J.TALO.2021.100072","volume":"4","author":"T Sajini","year":"2021","unstructured":"Sajini T, Mathew B. A brief overview of molecularly imprinted polymers: highlighting computational design, nano and photo-responsive imprinting. Talanta Open. 2021;4:100072. https:\/\/doi.org\/10.1016\/J.TALO.2021.100072.","journal-title":"Talanta Open"},{"issue":"1","key":"3414_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S40824-023-00388-5","volume":"27","author":"MS Kang","year":"2023","unstructured":"Kang MS, Cho E, Choi HE, Amri C, Lee JH, Kim KS. Molecularly imprinted polymers\u00a0(MIPs): emerging biomaterials for cancer theragnostic applications. Biomater Res. 2023;27(1):1\u201332. https:\/\/doi.org\/10.1186\/S40824-023-00388-5.","journal-title":"Biomater Res"},{"key":"3414_CR113","doi-asserted-by":"publisher","first-page":"100038","DOI":"10.1016\/J.JPBAO.2024.100038","volume":"4","author":"M Ovezova","year":"2024","unstructured":"Ovezova M, Y\u0131lmaz F, G\u00f6kt\u00fcrk I, G\u00fcler K\u00c7, Denizli A. Molecularly imprinted polymers for pharmaceutical and biomedical analysis. J Pharm Biomed Anal Open. 2024;4:100038. https:\/\/doi.org\/10.1016\/J.JPBAO.2024.100038.","journal-title":"J Pharm Biomed Anal Open"},{"key":"3414_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/J.JDDST.2024.105827","volume":"97","author":"D Karati","year":"2024","unstructured":"Karati D, Mukherjee S, Prajapati B, Bose A, Paul S, Elossaily GM, et al. A review on lipid-polymer hybrid nanocarriers in cancer. J Drug Deliv Sci Technol. 2024;97:105827. https:\/\/doi.org\/10.1016\/J.JDDST.2024.105827.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3414_CR115","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3390\/JFB14090437","volume":"14","author":"S Jain","year":"2023","unstructured":"Jain S, Kumar M, Kumar P, Verma J, Rosenholm JM, Bansal KK, et al. Lipid\u2013Polymer Hybrid Nanosystems: A Rational Fusion for Advanced Therapeutic Delivery. J Funct Biomater. 2023;14:437\u2013437. https:\/\/doi.org\/10.3390\/JFB14090437.","journal-title":"J Funct Biomater"},{"key":"3414_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2021.111302","volume":"137","author":"E Osta\u0144ska","year":"2021","unstructured":"Osta\u0144ska E, Aebisher D, Bartusik-Aebisher D. The potential of photodynamic therapy in current breast cancer treatment methodologies. Biomed Pharmacother. 2021;137:111302. https:\/\/doi.org\/10.1016\/J.BIOPHA.2021.111302.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"3414_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-024-02236-4","volume":"10","author":"G Li","year":"2024","unstructured":"Li G, Wang C, Jin B, Sun T, Sun K, Wang S, et al. Advances in smart nanotechnology-supported photodynamic therapy for cancer. Cell Death Discov. 2024;10(1):1\u201318. https:\/\/doi.org\/10.1038\/s41420-024-02236-4.","journal-title":"Cell Death Discov"},{"key":"3414_CR118","doi-asserted-by":"publisher","first-page":"101405","DOI":"10.1016\/J.NANOSO.2024.101405","volume":"40","author":"S Rajput","year":"2024","unstructured":"Rajput S, Malviya R, Sridhar SB. Nanoparticle-based photodynamic therapy for targeted treatment of breast cancer. Nano-Struct Nano-Objects. 2024;40:101405. https:\/\/doi.org\/10.1016\/J.NANOSO.2024.101405.","journal-title":"Nano-Struct Nano-Objects"},{"issue":"6","key":"3414_CR119","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s12276-023-01016-x","volume":"55","author":"SMP Vadevoo","year":"2023","unstructured":"Vadevoo SMP, Gurung S, Lee H-S, Gunassekaran GR, Lee S-M, Yoon J-W, et al. Peptides as multifunctional players in cancer therapy. Exp Mol Med. 2023;55(6):1099\u2013109. https:\/\/doi.org\/10.1038\/s12276-023-01016-x.","journal-title":"Exp Mol Med"},{"key":"3414_CR120","doi-asserted-by":"publisher","first-page":"74","DOI":"10.2174\/1871520617666170419143459","volume":"18","author":"N Zhao","year":"2018","unstructured":"Zhao N, Qin Y, Liu H, Cheng Z. Tumor-targeting peptides: ligands for molecular imaging and therapy. Anticancer Agents Med Chem. 2018;18:74\u201386. https:\/\/doi.org\/10.2174\/1871520617666170419143459.","journal-title":"Anticancer Agents Med Chem"},{"key":"3414_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2020.00221","volume":"10","author":"Y Haibe","year":"2020","unstructured":"Haibe Y, Kreidieh M, El Hajj H, Khalifeh I, Mukherji D, Temraz S, et al. Resistance mechanisms to anti-angiogenic therapies in cancer. Front Oncol. 2020;10:221. https:\/\/doi.org\/10.3389\/FONC.2020.00221.","journal-title":"Front Oncol"},{"key":"3414_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJPHAR.2023.175586","volume":"949","author":"S Ghalehbandi","year":"2023","unstructured":"Ghalehbandi S, Yuzugulen J, Pranjol MZI, Pourgholami MH. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. Eur J Pharmacol. 2023;949:175586. https:\/\/doi.org\/10.1016\/J.EJPHAR.2023.175586.","journal-title":"Eur J Pharmacol"},{"key":"3414_CR123","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/J.SEMCANCER.2022.03.011","volume":"86","author":"Y Yang","year":"2022","unstructured":"Yang Y, Cao Y. The impact of VEGF on cancer metastasis and systemic disease. Semin Cancer Biol. 2022;86:251\u201361. https:\/\/doi.org\/10.1016\/J.SEMCANCER.2022.03.011.","journal-title":"Semin Cancer Biol"},{"key":"3414_CR124","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/J.BIOPHA.2016.12.083","volume":"87","author":"C de A. Ferreira","year":"2017","unstructured":"de A. Ferreira C, Fuscaldi LL, Townsend DM, Rubello D, de Barros ALB. Radiolabeled bombesin derivatives for preclinical oncological imaging. Biomed Pharmacother. 2017;87:58\u201372. https:\/\/doi.org\/10.1016\/J.BIOPHA.2016.12.083.","journal-title":"Biomed Pharmacother"},{"key":"3414_CR125","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.3390\/PHARMACEUTICS15061648","volume":"15","author":"B Todaro","year":"2023","unstructured":"Todaro B, Ottalagana E, Luin S, Santi M. Targeting peptides: the new generation of targeted drug delivery systems. Pharmaceutics. 2023;15:1648. https:\/\/doi.org\/10.3390\/PHARMACEUTICS15061648.","journal-title":"Pharmaceutics"},{"key":"3414_CR126","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/PH15101283","volume":"15","author":"O Al Musaimi","year":"2022","unstructured":"Al Musaimi O, Lombardi L, Williams DR, Albericio F. Strategies for Improving Peptide Stability and Delivery. Pharmaceuticals. 2022;15:15. https:\/\/doi.org\/10.3390\/PH15101283.","journal-title":"Pharmaceuticals"},{"key":"3414_CR127","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2018.00790\/EPUB","volume":"9","author":"S Hua","year":"2018","unstructured":"Hua S, de Matos MBC, Metselaar JM, Storm G. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Front Pharmacol. 2018;9:403086. https:\/\/doi.org\/10.3389\/FPHAR.2018.00790\/EPUB.","journal-title":"Front Pharmacol"},{"key":"3414_CR128","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/J.JCONREL.2017.09.026","volume":"267","author":"F Wang","year":"2017","unstructured":"Wang F, Porter M, Konstantopoulos A, Zhang P, Cui H. Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy. J Control Release. 2017;267:100. https:\/\/doi.org\/10.1016\/J.JCONREL.2017.09.026.","journal-title":"J Control Release"},{"key":"3414_CR129","doi-asserted-by":"publisher","first-page":"1000164","DOI":"10.4172\/2157-7439.1000164","volume":"4","author":"P Ma","year":"2013","unstructured":"Ma P, Mumper RJ. Paclitaxel nano-delivery systems: a comprehensive review. J Nanomed Nanotechnol. 2013;4:1000164. https:\/\/doi.org\/10.4172\/2157-7439.1000164.","journal-title":"J Nanomed Nanotechnol"},{"key":"3414_CR130","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/J.IJBIOMAC.2022.04.209","volume":"210","author":"SJ Huang","year":"2022","unstructured":"Huang SJ, Wang TH, Chou YH, Wang HMD, Hsu TC, Yow JL, et al. Hybrid PEGylated chitosan\/PLGA nanoparticles designed as pH-responsive vehicles to promote intracellular drug delivery and cancer chemotherapy. Int J Biol Macromol. 2022;210:565\u201378. https:\/\/doi.org\/10.1016\/J.IJBIOMAC.2022.04.209.","journal-title":"Int J Biol Macromol"},{"key":"3414_CR131","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/14737140.2020.1732211","volume":"20","author":"SM Reddy","year":"2020","unstructured":"Reddy SM, Carroll E, Nanda R. Atezolizumab for the treatment of breast cancer. Expert Rev Anticancer Ther. 2020;20:151\u20138. https:\/\/doi.org\/10.1080\/14737140.2020.1732211.","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03414-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03414-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03414-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:49:31Z","timestamp":1780390171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03414-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":131,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["3414"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03414-6","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"There is no conflict of interest and disclosures associated with the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}